Market Research Logo

HIV: Markets for Diagnostics and Therapeutics

The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology.

In his report HIV Markets for Diagnostics and Therapeutics, anlayst Kenneth Krul, PhD examines these focal points, with an eye to creating a comprehensive look at the market and opportunity for both testing and treatments of HIV. Dr. Krul takes a look at the potential theoretical markets and what will be realistic in the current world healthcare system.

The report contains extensive epidemological statistics for HIV in the following WHO health regiions:

  • Sub-Saharan Africa
  • Middle East and North Africa
  • South and South-East Asia
  • East Asia
  • Latin America
  • Caribbean
  • Eastern Europe and Central Asia
  • Western and Central Europe
  • North America
  • Oceania
In addition the report contains:
  • Current Market Sizes for HIV Treatments and Diagnostics in each WHO Health Region (treatment and diagnostic markets)
  • Profiles of Companies in this Market
  • Eleven Important Conclusions
  • Review of Current Treatment Products and Diagnostic Tools.
As with all Kalorama Information reports, this product is the result of primary and secondary research. Interviews with experts, as well as research into company reports, medical literature and government data is included.


  • Executive Summary
    • Potential Market and Realistic Market
      • Table Estimated Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008 (Millions)
      • Table Regional HIV/AIDS Statistics: 2001 and 2007
      • Technology
      • Key HIV/AIDS Market Issues
    • SCOPE AND METHODOLOGY
  • Introduction and Epidemology
    • HIV/AIDS COMPLICATIONS
    • HIV/AIDS EPIDEMIOLOGY
      • Table Global Summary of HIV/AIDS Populations: 2007
      • Sub-Saharan Africa
        • Table Regional HIV/AIDS Statistics (I): 2001 and 2007 (Millions)
        • Table Regional HIV/AIDS Statistics (II): 2001 and 2007
        • Table Adult (Aged 14 - 49 years) HIV Prevalence in Sub-Saharan Countries That Have Recently Conducted Population-Based HIC Studies
      • Asia
      • Eastern Europe and Central Asia
      • The Caribbean
      • Latin America
      • North America, Western and Central Europe
        • Table AIDS Distribution by Race in the United States: 2006
        • Table Risk Factors Associated with AIDS in Men in the United States: 2006
        • Table Prevalence of HIV Infection in the United States Based on Sample Testing: 2006
        • Table Risk Factors Associated with AIDS in Women in the United States: 2006
    • The Middle East and North Africa
  • HIV/AIDS Screening and Diagnosis
    • SCREENING
    • CONFIRMATORY TESTING
    • DIAGNOSIS
      • Table HIV Screening and Confirmatory Testing Products Approved for Use in the United States as of July 9, 2008
      • Table Conditions Attributable to or Complicated by HIV
      • Table AIDS Indicator Conditions
    • MONITORING TREATMENT AND PROGNOSIS
  • HIV/AIDS Therapeutics
    • DRUG THERAPY
      • Table HIV Entry/Fusion Inhibitors; FDA-Approved and in Development: 2008
      • Table Nucleoside Reverse Transcription Inhibitors (NRTI); FDA-Approved and in Development: 2008
      • Table Non-Nucleoside Reverse Transcription Inhibitors (NNRTI); FDA-Approved and in Development: 2008
      • Table Integrase Inhibitors; FDA-Approved and in Development: 2008
      • Table Protease Inhibitors (PI)/Maturation Inhibitors (MI); FDA-Approved and in Development: 2008
    • PEDIATRIC HIV/AIDS
      • Table Anti-HIV Drugs in Development: 2008
      • Table Anti-HIV Drugs Approved for Pediatric Use
    • CHEMOKINE THERAPEUTICS AND HIV
    • GENES AND HIV/AIDS
    • HIV/AIDS VACCINES
  • Market Analysis
    • Table Estimated Theoretical Potential for HIV/AIDS Diagnostics and Therapeutics: 2008 (Millions)
    • Table Regional Distribution, HIV/AIDS Market
    • Table Estimated Realistic Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008 (Millions)
    • Technology
      • Key HIV/AIDS Market Issues
  • Company Snapshots
    • ABBOTT LABORATORIES
    • ABBOTT MOLECULAR DIAGNOSTICS
    • BRISTOL-MYERS SQUIBB
    • CALYPTE BIOMEDICAL CORP.
    • CELERA DIAGNOSTICS
    • GEN-PROBE INCORPORATED
    • GILEAD SCIENCES
    • GLAXOSMITHKLINE PLC
    • LUMINEX CORPORATION
    • QIAGEN GMBH
    • ROCHE MOLECULAR SYSTEMS
    • TIBOTEC,INC. (A JOHNSON &JOHNSON COMPANY)
    • VIRXSYS CORPORATION
  • Conclusions and Strategic Implications
    • FIRST CONCLUSION
    • SECOND CONCLUSION
    • THIRD CONCLUSION
    • FOURTH CONCLUSION
    • FIFTH CONCLUSION
    • SIXTH CONCLUSION
    • SEVENTH CONCLUSION
    • EIGHTH CONCLUSION
    • NINTH CONCLUSION
    • TENTH CONCLUSION
    • ELEVENTH CONCLUSION
  • Glossary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report